Patent Grant
7550419
This application relates to compositions useful in dentifrices and other oral care products. Particularly the invention relates to oral care compositions containing a surfactant agent consisting essentially of water soluble salts of monoalkyl and dialkyl phosphate esters. The invention includes oral care formulations including mono-, di-, and polyol phosphate esters as surface modification agents to change adhesion properties of these surfaces for hydrophobic as well as hydrophilic materials.
The various benefits of using a variety of phosphate esters, as their salts, in oral care formulations have been reported for decades. U.S. Pat. No. 4,152,421 refers to the use of alkali metal or alkanolamine salts of alkyl phosphate esters in dentifrice formulations. It cites the high foaming property of the high monoalkyl content phosphate esters (monoalkyl:dialkyl phosphate, or MAP:DAP, weight ratio of 70:30-100:0) as novel, in combination with the “known” property of having no substantial after effects on the tastes and flavors of foods and drinks, especially citrus juices. The concept and range of structures is expanded in a subsequent patent, U.S. Pat. No. 5,370,865, which emphasizes the pleasant taste of basic amino acid salts, specifically with lysine, arginine and histidine. Another early patent, U.S. Pat. No. 4,264,580, covers the incorporation of 0.2-1.0% of an anionic phosphate ester mixture (monoalkyl:dialkyl weight ratios of 1:10 to 10:1) to reduce the grain formation in a sodium lauryl sulfate-calcium carbonate composition to produce a smooth paste. U.S. Pat. No. 4,350,680 asserts reduction in the sloughing or desquamation of oral mucosa during tooth brushing action if at least 0.2% of an anionic phosphate ester surface active agent is used as an additional surfactant to sodium lauryl sulfate. U.S. Pat. No. 5,019,373 asserts special advantages for the incorporation of shorter alkyl chain (C6 to C9) dialkyl phosphate esters, particularly dioctyl phosphate. The phosphate ester concentration at 2-4 wt. % in the dentifrice formulation. Evidence for anti-caries activity was offered, which showed a lower rate of calcium demineralization on teeth (in vitro) treated with 1% dioctyl phosphate solution compared to both a 1% sodium lauryl sulfate, which was similar to plain water (placebo), and 1 ppm sodium fluoride (the positive control).
The present inventions uses mono-, di-, and polyol phosphate esters (like PEG phosphate esters, PPG phosphate esters, glycerine phosphate esters) to provide multiple benefits to oral care formulations. The concentrations in which they may be used can vary depending on the intended purpose and the amount of benefit desired. These molecules with a hydrophilic nature are expected to assist in removing stains from teeth. They may also assist in preventing staining of teeth by being adsorbed onto teeth. The oral hygiene compositions of the invention include: providing an ablatable coating for anti-adherence of stain and bacteria to teeth; desensitization of teeth having dentinal hypersensitivity; low irritancy and improved tissue compatibility or tolerance; increased deposition of various ingredients, including anti-microbials, flavor oils; compatibility with peroxide whitening agents; and anti-tartar characteristics.
In a first aspect, the present invention is directed to an oral care composition, comprising:
The invention further relates to the use of organophosphorus material in a dentifrice, particularly standard toothpaste.
The invention also relates to a tooth cleaning product comprising an organophosphorus material, an abrasive agent (polishing agent) and optionally a liquid.
The invention provides a mouthwash comprising:
Additionally, the longer term use of the organophosphorus material based dentifrice in accordance with the invention has an unexpectedly long lasting, beneficial therapeutic effect.
As used herein, the terminology “hydrophobic surface” means a surface that exhibits a tendency to repel water and to thus resist being wetted by water, as evidenced by a water contact angle of greater than or equal to 70°, more typically greater than or equal to 90°, and/or a surface free energy of less than or equal to about 40 dynes/cm.
As used herein, the terminology “hydrophilic surface” means a surface that exhibits an affinity for water and to thus be wettable by water, as evidenced by a water contact angle of less than 70°, more typically less than 60° and/or a surface energy of greater than about 40 dynes/cm, more typically greater than or equal to about 50 dynes/cm.
As used herein in reference to a hydrophobic surface, the term “hydrophilizing” means rendering such surface more hydrophilic and thus less hydrophobic, as indicated by a decreased water contact angle. One indication of increased hydrophilicity of a treated hydrophobic surface is a decreased water contact angle with a treated surface compared to the water contact angle with an untreated surface.
A used herein in reference to a substrate, the terminology “water contact angle” means the contact angle exhibited by a droplet of water on the surface as measured by a conventional image analysis method, that is, by disposing a droplet of water on the surface, typically a substantially flat surface, at 25° C., photographing the droplet, and measuring the contact angle shown in the photographic image.
Surface energy is estimated using the Young equation:
cos(θ)*γlv=γsv−γsl
with the contact angle θ, the interfacial energy γsv between the solid and the vapor phase, the interfacial energy γsl between the solid and the liquid phase, and the interfacial energy γlv between the liquid and the vapor phase, and γsv represents the surface energy of the solid.
As used herein, “molecular weight” in reference to a polymer or any portion thereof, means to the weight-average molecular weight (“Mw”) of said polymer or portion, wherein Mw of a polymer is a value measured by gel permeation chromatography and Mw of a portion of a polymer is a value calculated according to known techniques from the amounts of monomers, polymers, initiators and/or transfer agents used to make the said portion.
As used herein, the notation “(Cn-Cm)” in reference to an organic group or compound, wherein n and m are integers, means that the group or compound contains from n to m carbon atoms per such group or compound.
The oral formulation of the present invention may be in the form of a toothpaste or dentifrice. The term “dentifrice”, as used herein, means paste, gel, or liquid formulations unless otherwise specified. The dentifrice composition may be in any desired form, such as deep striped, surface striped, multilayered, having the gel surrounding the paste, or any combination thereof. Each dentifrice composition will be contained in a physically separated compartment of a dispenser and dispensed side-by-side.
The term “oral formulation” as used herein means the total dentifrice delivered to the oral surfaces. The oral formulation is a combination of the two or more dentifrice compositions. The oral formulation is a product, which in the ordinary course of usage, is not intentionally swallowed for purposes of systemic administration of particular therapeutic agents, but is rather retained in the oral cavity for a time sufficient to contact substantially all of the dental surfaces and/or oral tissues for purposes of oral activity.
The term “aqueous carrier” as used herein means any safe and effective materials for use in the oral compositions of the present invention. Such materials include abrasive polishing materials, peroxide sources, alkali metal bicarbonate salts, thickening materials, humectants, water, surfactants, titanium dioxide, flavor system, sweetening agents, xylitol, coloring agents, and mixtures thereof.
The present compositions comprise essential components, as well as optional components. The essential and optional components of the compositions of the present invention are described in the following paragraphs.
Compositions for oral care include a wide variety of products, such as toothpastes, mouthwashes, and rinses.
Organophosphorus Material
The present invention includes oral care compositions comprising a surface active agent and a hydrophyilizing agent comprising organophosphorus material selected from:
Suitable organophosphorus materials are also described in U.S. provisional patent application Nos. 60/842,265, filed Sep. 5, 2006 and 60/812,819, filed Jun. 12, 2006, both incorporated herein by reference.
As used herein, the term “alkyl” means a monovalent saturated straight chain or branched hydrocarbon radical, typically a monovalent saturated (C1-C30)hydrocarbon radical, such as for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, pentyl, or n-hexyl, which may optionally be substituted on one or more of the carbon atoms of the radical. In one embodiment, an alkyl radical is substituted on one or more carbon atoms of the radical with alkoxy, amino, halo, carboxy, or phosphono, such as, for example, hydroxymethyl hydroxyethyl, methoxymethyl, ethoxymethyl, isopropoxyethyl, aminomethyl, chloromethyl or trichloromethyl, carboxyethyl, or phosphonomethyl.
As used herein, the term “hydroxyalkyl” means an alkyl radical substituted on one of its carbon atoms with a hydroxyl group.
As used herein, the term “alkoxyl” means an oxy radical substituted with an alkyl group, such as for example, methoxyl, ethoxyl, propoxyl, isopropoxyl, or butoxyl, which may optionally be further substituted on one or more of the carbon atoms of the radical.
As used herein, the term “cycloalkyl” means a saturated cyclic hydrocarbon radical, typically a (C3-C8) saturated cyclic hydrocarbon radical, such as, for example, cyclohexyl or cyclooctyl, which may optionally be substituted on one or more of the carbon atoms of the radical.
As used herein, the term “alkenyl” means an unsaturated straight chain, branched chain, or cyclic hydrocarbon radical that contains one or more carbon-carbon double bonds, such as, for example, ethenyl, 1-propenyl, or 2-propenyl, which may optionally be substituted on one or more of the carbon atoms of the radical. As used herein, the term “aryl” means a monovalent unsaturated hydrocarbon radical containing one or more six-membered carbon rings in which the unsaturation may be represented by three conjugated double bonds, such as for example, phenyl, naphthyl, anthryl, phenanthryl, or biphenyl, which may optionally be substituted one or more of carbons of the ring. In one embodiment, an aryl radical is substituted on one or more carbon atoms of the radical with hydroxyl, alkenyl, halo, haloalkyl, or amino, such as, for example, methylphenyl, dimethylphenyl, hydroxyphenyl, chlorophenyl, trichloromethylphenyl, or aminophenyl.
As used herein, the term “aryloxy” means an oxy radical that is substituted with an aryl group, such as for example, phenyloxy, methylphenyl oxy, isopropylmethylphenyloxy.
As used herein, the indication that a radical may be “optionally substituted” or “optionally further substituted” means, in general, unless further limited, either explicitly or by the context of such reference, that such radical may be substituted with one or more inorganic or organic substituent groups, such as, for example, alkyl, alkenyl, aryl, aralkyl, alkaryl, a hetero atom, or heterocyclyl, or with one or more functional groups that are capable of coordinating to metal ions, such as hydroxyl, carbonyl, carboxyl, amino, imino, amido, phosphonic acid, or sulphonic acid, or inorganic and organic esters thereof, such as, for example, sulphate or phosphate, or salts thereof.
As used herein, the terminology “(Cx-Cy)” in reference to an organic group, wherein x and y are each integers, indicates the group may contain from x carbon atoms to y carbon atoms per group.
In one embodiment, R6 and R8 are each and each R7 is independently H, (C1-C30)alkyl, (C1-C30)alkenyl, or (C7-C30)alkaryl.
In one embodiment, each R1 and each R2 is O, and the organophosphorus compound is selected from:
In one embodiment, each R1 is absent, each R2 is O, and the organophosphorus compound is selected from:
In one embodiment, each R1 is O, each R2 is absent, and the organophosphorus compound is selected from:
In one embodiment, each R3 is a divalent radical according to structure (V), (VI), (VII), or (VIII):
wherein:
In one embodiment, each R4 and each R5 is independently absent or a divalent radical according to structure (V), (VI), or (VII), wherein R12, R13, R20, R21, R22, R23, p, p′, p″, q, r, r′, r″, s, t, t″, t, u, v, w, x, and y are as described above.
In one embodiment, each R3 is independently a divalent radical according to structure (V), (VI), or (VII) wherein R12, R13, R20, R21, R22, R23, p, p′, p″, q, r, r′, r″, s, t, t″, t, u, v, w, x, and y are as described above, and R4 and R5 are each independently absent or R3.
In one embodiment, each R3 is independently a divalent radical according to structure (V), wherein p is 2, 3, or 4, r is an integer from 1 to 25, s is 0, t is an integer of from 1 to 2, and R4 and R5 are each independently absent or R3.
In one embodiment, each R3 is independently a divalent radical according to structure (VI), wherein the R12 groups are fused to form, including the carbon atoms to which they are attached, a (C6-C8) hydrocarbon ring, each R13 is H, p′ is 2 or 3, u is 2, v is an integer of from 1 to 3, r′ is an integer from 1 to 25, t′ is an integer of from 1 to 25, the product of the quantity (v+r′) multiplied times t″ is less than or equal to about 100, more typically less than or equal to about 50, and R4 and R5 are each independently absent or R3.
In one embodiment, each R3 is independently a divalent radical according to structure (VII), wherein R20 is hydroxyl or hydroxyalkyl, R22 is H, alkyl, hydroxyl, or hydroxyalkyl, provided that R20 and R22 are not each hydroxyl, R21 and R23 are each independently methylene, di(methylene), or tri(methylene), w is 1 or 2, p″ is 2 or 3, r″ is an integer of from 1 to 25, t″ is an integer of from 1 to 25, the product of the quantity (w+r″) multiplied times t″ is less than or equal to about 100, more typically less than or equal to about 50, and R4 and R5 are each independently absent or R3.
In one embodiment of the organophosphorus compound according to structure (II):
R6 and R8 are each and each R7 is independently H or (C1-C30)hydrocarbon, which hydrocarbon may optionally be substituted on one or more carbon atoms by hydroxyl, fluorine, alkyl, alkenyl or aryl and/or interrupted at one or more sites by an O, N, or S heteroatom, or —POR9R10, more typically, R6, R8, and each R7 are each H,
R4 and R5 are each absent,
each R3 is independently a divalent radical according to structure (V), (VI), or (VII), and
m is an integer of from 1 to 5.
In one embodiment of the organophosphorus compound according to structure (II):
R6, R8, and each R7 are each H,
R4 and R5 are each absent,
each R3 is independently a divalent radical according to structure (V),
each p is independently 2, 3,or 4, more typically 2 or 3,
each r is independently a number of from 1 to about 100, more typically from
2 to about 50,
each s is 0,
each t is 1, and
m is an integer of from 1 to 5.
In one embodiment, the organophosphorus material is selected from:
In one embodiment of the organophosphorus compound according to structure (II):
R6, R8, and each R7 are each H,
R4 and R5 are each absent,
each R3 is independently a divalent radical according to structure (VI),
the R12 groups are fused to form, including the carbon atoms to which they are attached, a (C6-C8)hydrocarbon ring,
each R13 is H
p′ is 2 or 3,
u is 2,
v is 1,
r′ is a number of from 1 to 25,
t′ is a number of from 1 to 25,
the product of the quantity (v+r′) multiplied times t′ is less than or equal to about 100, and
m is an integer of from 1 to 5.
In one embodiment of the organophosphorus compound according to structure (II):
R6, R8, and each R7 are each H,
R4 and R5 are each absent,
each R3 is independently a divalent radical according to structure (VII),
R20 is hydroxyl or hydroxyalkyl,
R22 is H, alkyl, hydroxyl, or hydroxyalkyl,
R23 and R21 are each independently methylene, di(methylene), or tri(methylene),
w is 1 or 2,
p″ is 2 or 3,
r″ is a number of from 1 to 25,
t″ is a number of from 1 to 25
the product of the quantity (w+r″) multiplied times t″ is less than or equal to about 100, and
m is an integer of from 1 to 5.
In one embodiment, the organophosphorus compound is according to structure (III), each R3 is a divalent radical according to structure (V) with s=0 and t=1, R4 and R5 are each absent, and R6, R7, and R8 are each H.
In one embodiment, the organophosphorus compound is according to structure (IV), wherein R3 and R5 are each according to structure (V), with s=0 and t=1, and R6 and R8 are each H.
In one embodiment, the organophosphorus material (b)(I) comprises a condensation reaction product of two or more molecules according to structure (I).
In one embodiment, the organophosphorus material (b)(I) comprises a condensation reaction product of two or more molecules according to structure (I) in the form of a linear molecule, such as, for example, a linear condensation reaction product according to structure (X), formed by condensation of a molecule according to structure (II) with a molecule according to structure (IV):
wherein R4, R7, p, r are each as described above.
In one embodiment, the organophosphorus material (b)(I) comprises a condensation reaction product of two or more molecules according to structure (I) in the form of a crosslinked network. A portion of an exemplary crosslinked condensation reaction product network is illustrated by structure (XI):
wherein
R1, R2, R4, R5, R6, R7, R8, and m are each as described above, and
each R3′ is independently a residue of an R3 group of a compound according to structure (I), as described above, wherein the R3 group is a alkyleneoxy or poly(alkyleneoxy) moiety substituted with hydroxyl-, hydroxyalkyl-, hydroxyalkyleneoxy- or hydroxypoly(alkyleneoxy)- on one or more carbon atoms of the alkyleneoxy or poly(alkyleneoxy) moiety, and —R3′—R4— and —R3′—R5— each represent a respective linkage formed by condensation of such an R3 group and a —R3′—R5— or R8—R5— group of molecules of another molecule of a compound according to structure (I).
In one embodiment, the organophosphorus material (b)(I) comprises a condensation reaction product of two or more molecules according to structure (I) and the condensation reaction product forms a covalently crosslinked organophosphorus network. Typically the solubility of the covalently crosslinked organophosphorus network in water is less than that of the organophosphorus compound according to structure (I), more typically, the covalently crosslinked organophosphorus network is substantially insoluble in water.
As used herein, the term “salts” refers to salts prepared from bases or acids including inorganic or organic bases and inorganic or organic acids.
In one embodiment, the organophosphorus material (b)(I) is in the form of a salt that comprises an anion derived (for example, by deprotonation of a hydroxyl or a hydroxyalkyl substituent) from of an organophosphorus compound according to structure (I) and one or more positively charged counterions derived from a base.
Suitable positively charged counterions include inorganic cations and organic cations, such as for example, sodium cations, potassium cations, calcium cations, magnesium cations, copper cations, zinc cations, ammonium cations, tetraalkylammonium cations, as well as cations derived from primary, secondary, and tertiary amines, and substituted amines.
In one embodiment, the cation is a monovalent cation, such as for example, Na+, or K+.
In one embodiment, the cation is a polyvalent cation, such as, for example, Ca+2, Mg+2, Zn+2, Mn+2, Cu+2, Al+3, Fe+2, Fe+3, Ti+4, Zr+4, in which case the organophosphorus compound may be in the form of a “salt complex” formed by the organophosphorus compound and the polyvalent cation. For organophosphorus compound having two or more anionic sites, e.g., deprotonated hydroxyl substituents, per molecule, the organophosphorus compound-polyvalent cation complex can develop an ionically crosslinked network structure. Typically the solubility of the ionically crosslinked organophosphorus network in water is less than that of the organophosphorus compound according to structure (I), more typically, the ionically crosslinked organophosphorus network is substantially insoluble in water.
Suitable organophosphorus compounds can be made by known synthetic methods, such as by reaction of one or more compounds, each having two or more hydroxyl groups per molecule, with phosphoric acid, polyphosphoric acid, and or phosphoric anhydride, such as disclosed, for example, in U.S. Pat. Nos. 5,550,274, 5,554,781, and 6,136,221.
In one embodiment, cations are immobilized on a water insoluble substrate to form a water insoluble cationic particle and the hydophilizing layer further comprises cationic particles. Suitable substrates include inorganic oxide particles, including for example, oxides of single elements, such as cerium oxide, titanium oxide, zirconium oxide, halfnium oxide, tantalum oxide, tungsten oxide, silicon dioxide, and bismuth oxide, zinc oxide, indium oxide, and tin oxide, and mixtures of such oxides, as well as oxides of mixtures of such elements, such as cerium-zirconium oxides. Such particle may exhibit a mean particle diameter (“D50”) of from about 1 nanometer (“nm”) to about 50 micrometers (“μm”), more typically from about 5 to about 1000 nm, even more typically from about 10 to about 800 nm, and still more typically from about 20 to about 500 nm, as determined by dynamic light scattering or optical microscopy. In one embodiment, aluminum cations are immobilized on silica particles.
Vinyl Alcohol Material
In one embodiment, the oral care product comprises a vinyl alcohol material (b)(II) as a hydrophilizing material.
In one embodiment, which offers improved solubility in water and improved processability, the vinyl alcohol material (b)(II) comprises a polymer that comprises monomeric units according to structure (I-a) (a “vinyl alcohol polymer”).
In one embodiment, the vinyl alcohol polymer and exhibits a weight average molecular weight of greater than or equal to about 10,000, more typically from about 10,000 to about 100,000, even more typically from about 10,000 to about 30,000. In an alternative embodiment, which offers improved durability, the vinyl alcohol polymer a weight average molecular weight of greater than or equal to about 100,000, more typically form about 100,000 to about 200,000. In another embodiment, which offers a balance between processability and durability, the vinyl alcohol polymer exhibits a weight average molecular weight of greater than or equal to about 50,000, more typically from about 50,000 to about 150,000, even more typically from about 80,000 to about 120,000.
In one embodiment, the vinyl alcohol polymer is made by polymerizing a vinyl ester monomer, such as for example, vinyl acetate, to form a polymer, such as a poly(vinyl acetate) homopolymer or a copolymer comprising monomeric units derived from vinyl acetate, having a hydrocarbon backbone and ester substituent groups, and then hydrolyzing at least a portion of the ester substitutent groups of the polymer to form hydroxy-substituted monomeric units according to structure (I-a). In one embodiment, which offers improved solubility in water and improved processability, the vinyl alcohol polymer exhibits a degree of hydrolysis of greater than or equal to about 88%, more typically from about 88% to about 95%. As used herein in reference to a vinyl alcohol polymer that is made by hydrolyzing a polymer initially having a hydrocarbon backbone and ester substituent groups, the term “degree of hydrolysis” means the relative amount, expressed as a percentage, of vinyl ester-substituted monomeric units that were hydrolyzed to form hydroxy-substituted monomeric units. In another embodiment, which offers improved solubility in water and improved durability, the vinyl alcohol polymer exhibits a degree of hydrolysis of greater than or equal to about 99%. In yet another embodiment, which offers a compromise between solubility in water and durability, the polymer exhibits a degree of hydrolysis from about 92 to about 99%.
In one embodiment, the vinyl alcohol polymer has a linear polymeric structure. In an alternative embodiment, the vinyl alcohol polymer has a branched polymeric structure.
In one embodiment, the vinyl alcohol polymer is a vinyl alcohol homopolymer that consists solely of monomeric units according to structure (I-a).
In one embodiment, the vinyl alcohol polymer is a vinyl alcohol copolymer that comprises monomeric units having a structure according to structure (I-a) and further comprises comonomeric units having a structure other than structure (I-a). In one embodiment, the vinyl alcohol polymer is a copolymer that comprises hydroxy-substituted monomeric units according to (I-a) and ester substituted monomeric units and is made by incomplete hydrolysis of a vinyl ester homopolymer.
In one embodiment a vinyl alcohol copolymer comprises greater than or equal to about 50 mole % (“mol %”), more typically greater or equal to than about 80 mol %, monomeric units according to structure (I-a) and less than about 50 mol %, more typically less than about 20 mol %, comonomeric units having a structure other than structure (I-a).
As described above, vinyl alcohol polymers having monomeric units according to structure (I-a) are typically derived from polymerization of vinyl ester monomers and subsequent hydrolysis of vinyl ester-substituted monomeric units of the polymer. Suitable vinyl alcohol copolymers are typically derived by copolymerization of the vinyl ester monomer with any ethylenically unsaturated monomer that is copolymerizable with the vinyl ester monomer, including for example, other vinyl monomers, allyl monomers, acrylic acid, methacrylic acid, acrylic ester monomers, methacrylic ester monomers, acrylamide monomers, and subsequent hydrolysis of at least a portion of the ester-substituted monomeric units to form hydroxy-substituted monomeric units according to structure (I-a).
In one embodiment, the vinyl alcohol polymer comprises monomeric units according to structure (I-a) and further comprises hydrophilic monomeric units other than the monomeric according to structure (I-a). As used herein, the term “hydrophilic monomeric units” are those wherein homopolymers of such monomeric units are soluble in water at 25° C. at a concentration of 1 wt % homopolymer, and include, for example, monomeric units derived from, for example, hydroxy(C1-C4)alkyl(meth)acrylates, (meth)acrylamide, (C1-C4)alkyl(meth)acrylamides, N,N-dialkyl-acrylamides, alkoxylated(meth)acrylates, poly(ethylene glycol)-mono methacrylates and poly(ethyleneglycol)-monomethylether methacrylates, hydroxy(C1-C4)acrylamides and methacrylamides, hydroxyl(C1-C4)alkyl vinyl ethers, N-vinylpyrrole, N-vinyl-2-pyrrolidone, 2- and 4-vinylpyridine, ethylenically unsaturated carboxylic acids having a total of 3 to 5 carbon atoms, amino(C1-C4)alkyl, mono(C1-C4)alkylamino(C1-C4)alkyl, and di(C1-C4)alkylamino(C1-C4)alkyl (meth)acrylates, allyl alcohol, dimethylaminoethyl methacrylate, dimethylaminoethylmethacrylamide.
In one embodiment, the vinyl alcohol polymer comprises monomeric units according to structure (I-a) and further comprises hydrophobic monomeric units. As used herein, the term “hydrophobic monomeric units” are those wherein homopolymers of such monomeric units are insoluble in water at 25° C. at a concentration of 1 wt % homopolymer, and include, for example, monomeric units derived from (C1-C18)alkyl and (C5-C18)cycloalkyl (meth)acrylates, (C5-C18)alkyl(meth)acrylamides, (meth)acrylonitrile, vinyl (C1-C18)alkanoates, (C2-C18)alkenes, (C2-C18)haloalkenes, styrene, (C1-C6)alkylstyrenes, (C4-C12)alkyl vinyl ethers, fluorinated (C2-C10)alkyl (meth)acrylates, (C3-C12)perfluoroalkylethylthiocarbonylaminoethyl(meth)acrylates, (meth)acryloxyalkylsiloxanes, N-vinylcarbazole, (C1-C12) alkyl maleic, fumaric, itaconic, and mesaconic acid esters, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, chloroprene, vinyl chloride, vinylidene chloride, vinyltoluene, vinyl ethyl ether, perfluorohexyl ethylthiocarbonylaminoethyl methacrylate, isobornyl methacrylate, trifluoroethyl methacrylate, hexa-fluoroisopropyl methacrylate, hexafluorobutyl methacrylate, tristrimethylsilyloxysilylpropyl methacrylate, and 3-methacryloxypropylpentamethyldisiloxane.
As used herein, the term “(meth)acrylate” means acrylate, methacrylate, or acrylate and methacrylate and the term (meth)acrylamide” means acrylamide, methacrylamide or acrylamide and methacrylamide.
In one embodiment, the polymer comprising monomeric units according to structure (I-a) a random copolymer. In another embodiment, the copolymer comprising monomeric units according to structure (I-a) is a block copolymer.
Methods for making suitable vinyl alcohol polymers are known in the art. In one embodiment, a polymer comprising monomeric units according to structure (I-a) is made by polymerizing one or more ethylenically unsaturated monomers, comprising at least one vinyl ester monomer, such vinyl acetate, by known free radical polymerization processes and subsequently hydrolyzing at least a portion of the vinyl ester monomeric units of the polymer to make a polymer having the desired degree of hydrolysis. In another embodiment, the polymer comprising monomeric units according to structure (I-a) is a copolymer made by known controlled free radical polymerization techniques, such as reversible addition fragmentation transfer (RAFT), macromolecular design via interchange of xanthates (MADIX), or atom transfer reversible polymerization (ATRP).
In one embodiment, the vinyl alcohol polymer is made by known solution polymerization techniques, typically in an aliphatic alcohol reaction medium.
In another embodiment, the vinyl alcohol polymer is made by known emulsion polymerization techniques, in the presence of one or more surfactants, in an aqueous reaction medium.
In one embodiment, the vinyl alcohol material comprises a microgel made by crosslinking molecules of a vinyl alcohol polymer.
In one embodiment the vinyl alcohol material comprises a salt, such as a sodium or potassium salt, of a vinyl alcohol polymer.
Compositions
The organophosphorus material described herein may also be used in a variety of oral care products. The composition according to the invention can be provided in any form and can be used in multiple ways. Thus, it can be in the form of a paste, gel or liquid. For example, the organophosphorus material may be used in toothpastes (as described by U.S. Pat. No. 5,939,052), and mouth detergents (as described by U.S. Pat. No. 6,767,560), and other dentifrices (as described by U.S. Patent Application Publication No. 2004/0185207). Each of the documents discussed in this paragraph are expressly incorporated by reference in their entireties.
A toothpaste or gel in accordance with the invention will generally comprise an organophosphorus material as described above, a surfactant agent, a compatible abrasive agent system, and a liquid in an amount to provide the desired consistency.
In an exemplary toothpaste, the liquid may include water, humectant and binder, generally, in an amount ranging from about 10 to about 90% by weight of the toothpaste. Water is a desirable component when a toothpaste or gel is being prepared. Water comprises up to about 50%, and preferably about 5-35% by weight of the toothpaste. However, an anhydrous toothpaste or gel can be formulated if desired.
A tooth powder in accordance with the invention may comprise a polishing agent which is compatible with the soluble monoalkyl and dialkyl phosphate ester salts described herein, such as sodium bicarbonate or hydrated silica. Generally, the polishing agent will be in an amount from about 20 to about 95%, and preferably above 50% by weight of the formulation. An effective amount of the monoalkyl and dialkyl phosphate esters as described herein is typically from about 0.1 to about 10% and preferably about 1% to about 5% by weight of the tooth powder formulation. Optional, but preferred, components which may be included in the toothpowder are a flavoring agent and/or sweetening agent, an anti-calculus agent such as a water-soluble alkali metal salt of a polyphosphate, an anti-caries agent such as sodium fluoride or sodium monofluorophosphate, buffering agents such as alkali metal orthophosphates, phosphoric acid, alkali metal glycerophosphates, tartrates, or citrates, and one or more processing aids such as a flow aid to insure product uniformity.
A mouthwash in accordance with the invention generally comprises alcohol, water, humectant, and optionally an effective amount of the monoalkyl and dialkyl phosphate ester salts as described herein. An effective amount of the monoalkyl and dialkyl phosphate ester salts in the mouthwash is typically from about 0.1% to about 10% and preferably from about 1% to about 5% by weight of the mouthwash. Optional, but preferred, components which are included in the mouthwash are a flavoring agent and/or sweetening agent, an anti-calculus agent such as a water-soluble alkali metal salt of a polyphosphate, an anti-caries agent such as sodium fluoride or sodium monofluorophosphate, buffering agents such as alkali metal orthophosphates, phosphoric acid, alkali metal glycerophosphates, tartrates, or citrates.
As used herein, terms “aqueous medium” and “aqueous media” are used herein to refer to any liquid medium of which water is a major component. Thus, the term includes water per se as well as aqueous solutions and dispersions. For example, the aqueous medium may be a liquid bodily discharge, such as urine, menses, and saliva.
In one embodiment, the oral care composition comprises, based on 100 parts by weight (“pbw”) of the composition, from about 0.1 to about 20 pbw, more typically, from about 1 to about 5 pbw, organophosphorus material, and from about 80 to 99 pbw, more typically, from about 90 to about 98 pbw, carrier.
The pH of the composition or the pH of use of the composition according to the invention can vary, depending on the application. The pH of the compositions is not critical and can be in the range of from about 2 to about 12, preferably from about 4 to about 10 and most preferably from about 6 to about 8. The pH can be adjusted using a buffer such as citric acid.
The oral care composition of the invention can comprise, depending on its application, from 0.001 to 10% of its weight of at least one of the organophosphorus materials (phosphate esters).
The composition can be employed in an amount such that, after optional rinsing, the amount of phosphate esters deposited on the tooth surface is typically from 0.0001 to 10 mg/m2, for example, 0.001 to 5 mg/m2, of surface treated.
Unless otherwise indicated, when molar mass is referred to, the reference will be to the weight-average molar mass, expressed in g/mol. The latter can be determined by aqueous gel permeation chromatography (GPC) or by light scattering (DLS or alternatively MALLS), with an aqueous eluent or an organic eluent (for example dimethylacetamide, dimethylformamide, and the like), depending on the composition of the polymer.
Additional Ingredients
In addition to the organophosphorus material of the present invention, oral care products, such as mouthwashes, chewing gum, soluble oral care strips (similar to the LISTERINE® oral care strips), lozenges and toothpastes, of the present invention contain adjunct ingredients. Additional background on such products is provided by PCT application serial number PCT/US98/04474, filed Mar. 6, 1998 and published as WO 98/38973, as well as by U.S. Pat. No. 6,864,314, each of which is incorporated herein by reference in its entirety.
An oral hygiene composition in accordance with the invention may comprise, without intended limitation, components customarily used in this field, such as a polishing agent (abrasive agent), sudsing agents (surfactants), a binder, a humectant, a medicinal agent, peroxide sources, alkali metal bicarbonate salts, thickening materials, water, titanium dioxide, flavor agents, sweetening agents, xylitol, coloring agents, water and mixtures thereof. A popular, commercial anti-sensitivity agent is potassium nitrate. In preparing the present oral care compositions, it is desirable to add one or more of these additional ingredients to the compositions. Such materials are well known in the art and are readily chosen by one skilled in the art based on the physical and aesthetic properties desired for the compositions being prepared. These additional ingredients typically comprise from about 40% to about 99%, preferably from about 70% to about 98%, and more preferably from about 90% to about 95%, by weight of the dentifrice composition.
For example, optional, but preferred, components which may be included in oral care products in accordance with the invention are organic binders; inorganic thickeners, such as silica; secondary surfactants and/or sweetening agents; coloring agents and/or pigments; anti-microbial agents; and like components conventionally added to toothpastes and gels. Binders suitable for use in a composition of the invention include hydroxyethyl cellulose, and hydroxypropyl cellulose, as well as xanthan gums, Iris moss and gum tragacanth. Binders may be present in the amount from 0.01 to 10%. Sweeteners suitable for use, e.g. saccharin, may be present at levels of about 0.1% to 5%.
Abrasive Polishing Materials
An abrasive polishing material may also be included in the toothpaste compositions. The abrasive polishing material contemplated for use in the compositions of the present invention can be any material which does not excessively abrade dentin. Typical abrasive polishing materials include silicas including gels and precipitates; aluminas; phosphates including inorganic orthophosphates, pyrophosphates, metaphosphates, polyphosphates and hexametaphosphate salts; and mixtures thereof. Specific examples include dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, insoluble sodium polymetaphosphate, hydrated alumina, beta calcium pyrophosphate, calcium carbonate, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and others such as disclosed by Cooley et al in U.S. Pat. No. 3,070,510, issued Dec. 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
Silica dental abrasives of various types are preferred because of their unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentine. The silica abrasive polishing materials herein, as well as other abrasives, generally have an average particle size ranging between about 0.1 to about 30 microns, and preferably from about 5 to about 15 microns. The abrasive can be precipitated silica or silica gels such as the silica xerogels described in Pader et al., U.S. Pat. No. 3,538,230, issued Mar. 2, 1970, and DiGiulio, U.S. Pat. No. 3,862,307, issued Jan. 21, 1975, both incorporated herein by reference. Preferred are the silica xerogels marketed under the trade name “Syloid” by the W. R. Grace & Company, Davison Chemical Division. Also preferred are the precipitated silica materials such as those marketed by the J. M. Tuber Corporation under the trade name, “Zeodent”, particularly the silica carrying the designation “Zeodent 119”. The types of silica dental abrasives useful in the toothpastes of the present invention are described in more detail in Wason, U.S. Pat. No. 4,340,583, issued Jul. 29, 1982, incorporated herein by reference. Silica abrasives described in U.S. patent application Ser. Nos. 08/434,147 and 08/434,149, both filed May 2, 1995, are also herein incorporated by reference. The abrasive in the toothpaste compositions described herein is generally present at a level of from about 6% to about 70% by weight of the composition. Preferably, toothpastes contain from about 10% to about 50% of abrasive, by weight of the dentifrice composition.
Humectants
A humectant is also a desirable component in an oral care product, for example, toothpaste or gel. The humectant generally comprises from about 0% to 85%, and preferably from about 15% to 55%, by weight of the oral care composition. Preferably for toothpaste or gel, the humectant comprises about 5% to about 85% by weight of the formulation, and preferably from about 10% to about 70% by weight of the formulation. In translucent gels, where the refractive index is an important consideration, it is preferred to use higher ratios of humectant to water than in opaque pastes. For a gel the ratio of humectant to water should preferably be above about 0.5 to 1, and more preferably above 1 to 1.
Humectants contemplated for use in a composition of the invention include polyols, such as glycerol, sorbitol, polyethylene glycols, propylene glycol, hydrogenated partially hydrolyzed polysaccharides and the like. Exemplary amounts are provided below with reference to various types of compositions.
The humectant serves to keep toothpaste compositions from hardening upon exposure to air and certain humectants can also impart desirable sweetness of flavor to toothpaste compositions. Suitable humectants for use in the invention include glycerin, sorbitol, polyethylene glycol, propylene glycol, and other edible polyhydric alcohols.
Anti-caries Agent
Anti-caries agents may also be used in conjunction with the composition in accordance with the invention. Thus, the oral care composition of the present invention can incorporate a soluble fluoride source capable of providing free fluoride ions. For example oral hygiene compositions in accordance with the invention may include those commonly used in oral health care compositions, such as sodium fluoride, stannous fluoride, indium fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride and cobalt ammonium fluoride and the like. The present compositions contain a soluble fluoride ion source capable of providing from about 50 ppm to about 3500 ppm, and preferably from about 500 ppm to about 3000 ppm of free fluoride ions. Sodium fluoride is the most preferred soluble fluoride ion source. Norris et al., U.S. Pat. No. 2,946,725, issued Jul. 26, 1960, and Widder et al., U.S. Pat. No. 3,678,154 issued Jul. 18, 1972, disclose such fluoride ion sources as well as others. Both patents are incorporated herein by reference in their entirety.
Dyes/Colorants
Dyes/colorants suitable for oral health care compositions, i.e. FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc., may be included as well. Various other optional ingredients may also be included in the compositions of the invention such as preservatives; vitamins, for example, vitamins C and E; and other anti-plaque agents, for example, stannous salts, copper salts, strontium salts and magnesium salts. Compositions may also include anti-calculus agents such as a water-soluble alkali metal salt of a polyphosphate, buffering agents such as alkali metal orthophosphates, phosphoric acid, alkali metal glycerophosphates, tartrates, or citrates, other anti-caries agents, for example, calcium glycerophosphate, sodium trimetaphosphate; anti-staining compounds, for example silicone polymers; plant extracts; and mixtures thereof. Additionally, polymers, particularly anionic polymers, such as polycarboxylates or polysulfonates, or polymers containing both a carboxylate and a sulfonate moiety, or phosphonate polymers may be used.
Buffering Agents
The present compositions each may contain a buffering agent. Buffering agents, as used herein, refer to agents that can be used to adjust the pH of the compositions to a range of about pH 6.5 to about pH 10. These agents include alkali metal hydroxides, carbonates, sesquicarbonates, borates, silicates, phosphates, imidazole, and mixtures thereof. Specific buffering agents include monosodium phosphate, trisodium phosphate, sodium hydroxide, potassium hydroxide, alkali metal carbonate salts, sodium carbonate, imidazole, pyrophosphate salts, citric acid, and sodium citrate. Buffering agents are used at a level of from about 0.1% to about 30%, preferably from about 1% to about 10%, and more preferably from about 1.5% to about 3%, by weight of the present composition.
Inorganic pyrophosphate salts are also suitable buffering agents. The pyrophosphate salts include the dialkali metal pyrophosphate salts, tetra alkali metal pyrophosphate salts, and mixtures thereof. Disodium dihydrogen pyrophosphate (Na2H2P2O7), tetrasodium pyrophosphate (Na4P2O7), and tetrapotassium pyrophosphate (K4P2O7) in their unhydrated as well as hydrated forms are the preferred species. In compositions of the present invention, the pyrophosphate salt may be present in one of three ways: predominately dissolved, predominately undissolved, or a mixture of dissolved and undissolved pyrophosphate.
Compositions comprising predominately dissolved pyrophosphate refer to compositions where at least one pyrophosphate ion source is in an amount sufficient to provide at least about 1.0% free pyrophosphate ions. The amount of free pyrophosphate ions may be from about 1% to about 15%, preferably from about 1.5% to about 10%, and most preferably from about 2% to about 6%, by weight of the composition. Free pyrophosphate ions may be present in a variety of protonated states depending on the pH of the composition.
Compositions comprising predominately undissolved inorganic pyrophosphate refer to compositions containing no more than about 20% of the total pyrophosphate salt dissolved in the composition, preferably less than about 10% of the total pyrophosphate dissolved in the composition. Tetrasodium pyrophosphate salt is the preferred pyrophosphate salt in these compositions. Tetrasodium pyrophosphate may be the anhydrous salt form or the decahydrate form, or any other species stable in solid form in the dentifrice compositions. The salt is in its solid particle form, which may be its crystalline and/or amorphous state, with the particle size of the salt preferably being small enough to be aesthetically acceptable and readily soluble during use. The amount of pyrophosphate salt useful in making these compositions is any tartar control effective amount, and is generally from about 1.5% to about 15%, preferably from about 2% to about 10%, and most preferably from about 2.5% to about 8%, by weight of the composition. Some or all of the tetrasodium pyrophosphate may be undissolved in the product and present as tetrasodium pyrophosphate particles. Pyrophosphate ions in different protonated states (e.g., HP2O7−3) may also exist depending upon the pH of the composition and if part of the tetrasodium pyrophosphate is dissolved.
Compositions may also comprise a mixture of dissolved and undissolved pyrophosphate salts. Any of the above mentioned pyrophosphate salts may be used.
The pyrophosphate salts are described in more detail in Kirk & Othmer, Encyclopedia of Chemical Technology, Third Edition, Volume 17, Wiley-Interscience Publishers (1982), incorporated herein by reference in its entirety, including all references incorporated into Kirk & Othmer.
Optional agents to be used in place of or in combination with the pyrophosphate salt include such materials known to be effective in reducing calcium phosphate mineral deposition related to calculus formation. Agents included are synthetic anionic polymers [including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez), as described, for example, U.S. Pat. No. 4,627,977, to Gaffar et al., the disclosure of which is incorporated herein by reference in its entirety; as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof.
Thickening Agents
The present invention compositions in the form of toothpastes typically contain some thickening material or binders to provide a desirable consistency. Preferred thickening agents are carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose, and water soluble salts of cellulose ethers such as sodium carboxymethylcellulose and sodium hydroxyethyl cellulose. Natural gums such as gum karaya, xanthan gum, gum arabic, and gum tragacanth can also be used. Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture. Thickening agents can be used in an amount from about 0.1% to about 15%, by weight of the dentifrice composition.
Water
Water employed in the preparation of commercially suitable oral compositions should preferably be of low ion content and free of organic impurities. Water can generally comprise from about 5% to about 70%, and preferably from about 10% to about 50%, by weight of the composition herein. The amounts of water include the free water which is added plus that which is introduced with other materials, such as with sorbitol, silica, surfactant solutions, and/or color solutions.
Peroxide
The present invention may include a peroxide source in the composition. The peroxide source can be selected from the group consisting of hydrogen peroxide, calcium peroxide, urea peroxide, and mixtures thereof. The preferred peroxide source is calcium peroxide. The following amounts represent the amount of peroxide raw material, although the peroxide source may contain ingredients other than the peroxide raw material. The present composition may contain from about 0.01% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.2% to about 3%, and most preferably from about 0.3% to about 0.8% of a peroxide source, by weight of the dentifrice composition.
Alkali Metal Bicarbonate Salt
The present invention may also include an alkali metal bicarbonate salt. Alkali metal bicarbonate salts are soluble in water and unless stabilized, tend to release carbon dioxide in an aqueous system. Sodium bicarbonate, also known as baking soda, is the preferred alkali metal bicarbonate salt. The alkali metal bicarbonate salt also functions as a buffering agent. The present composition may contain from about 0.5% to about 50%, preferably from about 0.5% to about 30%, more preferably from about 2% to about 20%, and most preferably from about 5% to about 18% of an alkali metal bicarbonate salt, by weight of the dentifrice composition.
Sudsing Agents
The present compositions may also comprise surfactants, also commonly referred to as sudsing agents. Suitable surfactants are those which are reasonably stable and foam throughout a wide pH range. The surfactant may be anionic, nonionic, amphoteric, zwitterionic, cationic, or mixtures thereof. Anionic surfactants useful herein include the water-soluble salts of alkyl sulfates having from 8 to 20 carbon atoms in the alkyl radical (e.g., sodium alkyl sulfate) and the water-soluble salts of sulfonated monoglycerides of fatty acids having from 8 to 20 carbon atoms. Sodium lauryl sulfate and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type. Other suitable anionic surfactants are sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate. Mixtures of anionic surfactants can also be employed. Many suitable anionic surfactants are disclosed by Agricola et al., U.S. Pat. No. 3,959,458, issued May 25, 1976, incorporated herein in its entirety by reference. Nonionic surfactants which can be used in the compositions of the present invention can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkyl-aromatic in nature. Examples of suitable nonionic surfactants include poloxamers (sold under trade name Pluronic), polyoxyethylene, polyoxyethylene sorbitan esters (sold under trade name TWEENS), fatty alcohol ethoxylates, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides, and mixtures of such materials. The amphoteric surfactants useful in the present invention can be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be a straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water-solubilizing group, e.g., carboxylate, sulfonate, sulfate, phosphate, or phosphonate. Other suitable amphoteric surfactants are betaines, specifically cocamidopropyl betaine. Mixtures of amphoteric surfactants can also be employed. Many of these suitable nonionic and amphoteric surfactants are disclosed by Gieske et al., U.S. Pat. No. 4,051,234, issued Sep. 27, 1977, incorporated herein by reference in its entirety. The present composition typically comprises one or more surfactants each at a level of from about 0.25% to about 12%, preferably from about 0.5% to about 8%, and most preferably from about 1% to about 6%, by weight of the composition.
Colorants
Titanium dioxide may also be added to the present composition. Titanium dioxide is a white powder which adds opacity to the compositions. Titanium dioxide generally comprises from about 0.25% to about 5%, by weight of the composition.
Other coloring agents may also be added to the present composition. The coloring agent may be in the form of an aqueous solution, preferably 1% coloring agent in a solution of water. Color solutions generally comprise from about 0.01% to about 5%, by weight of the composition.
Dyes/colorants suitable for oral health care compositions, i.e. FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc., may be included as well. Various other optional ingredients may also be included in the compositions of the invention such as preservatives; vitamins, for example, vitamins C and E; and other anti-plaque agents, for example, stannous salts, copper salts, strontium salts and magnesium salts. Compositions may also include anti-calculus agents such as a water-soluble alkali metal salt of a polyphosphate, buffering agents such as alkali metal orthophosphates, phosphoric acid, alkali metal glycerophosphates, tartrates, or citrates, other anti-caries agents, for example, calcium glycerophosphate, sodium trimetaphosphate; anti-staining compounds, for example silicone polymers; plant extracts; and mixtures thereof. Additionally, polymers, particularly anionic polymers, such as polycarboxylates or polysulfonates, or polymers containing both a carboxylate and a sulfonate moiety, or phosphonate polymers may be used.
Flavor and Sweetening Agents
A flavor system can also be added to the compositions. Suitable flavoring components include oil of wintergreen, oil of peppermint, oil of spearmint, clove bud oil, menthol, anethole, methyl salicylate, eucalyptol, cassia, 1-menthyl acetate, sage, eugenol, parsley oil, oxanone, alpha-irisone, marjoram, lemon, orange, propenyl guaethol, cinnamon, vanillin, ethyl vanillin, heliotropine, 4-cis-heptenal, diacetyl, methyl-para-tert-butyl phenyl acetate, and mixtures thereof. Coolants may also be part of the flavor system. Preferred coolants in the present compositions are the paramenthan carboxyamide agents such as N-ethyl-p-menthan-3-carboxamide (known commercially as “WS-3”) and mixtures thereof. A flavor system is generally used in the compositions at levels of from about 0.001% to about 5%, by weight of the composition.
The present invention may also include xylitol. Xylitol is a sugar alcohol that is used as a sweetener and humectant. Xylitol may provide a therapeutic effect, such as an antibacterial or anticaries effect. The present compositions typically comprise xylitol at a level from about 0.01% to about 25%, preferably from about 3% to about 15%, more preferably from about 5% to about 12%, and most preferably from about 9% to about 11%, by weight of the total composition. Alternatively, if xylitol is used as a sweetener, it may be present at a lower level, such as from about 0.005% to about 5%, by weight of the dentifrice composition.
Other sweetening agents can be added to the compositions. These include saccharin, dextrose, sucrose, lactose, maltose, levulose, aspartame, sodium cyclamate, D-tryptophan, dihydrochalcones, acesulfame, and mixtures thereof. Various coloring agents may also be incorporated in the present invention. Sweetening agents and coloring agents are generally used in toothpastes at levels of from about 0.005% to about 5%, by weight of the composition.
Antibacterial and Antimicrobial Agents
The present invention may also include other agents, such as antibacterial agents and antimicrobial agents. Suitable antibacterial agents include phenolics and salicylamides.
Also, included among such agents are water insoluble non-cationic antimicrobial agents such as halogenated diphenyl ethers, phenolic compounds including phenol and its homologs, mono and poly-alkyl and aromatic halophenols, resorcinol and its derivatives, bisphenolic compounds and halogenated salicylanilides, benzoic esters, and halogenated carbanilides. The water soluble antimicrobials include quaternary ammonium salts and bis-biquanide salts, among others. Triclosan monophosphate is an additional water soluble antimicrobial agent. The quaternary ammonium agents include those in which one or two of the substitutes on the quaternary nitrogen has a carbon chain length (typically alkyl group) from about 8 to about 20, typically from about 10 to about 18 carbon atoms while the remaining substitutes (typically alkyl or benzyl group) have a lower number of carbon atoms, such as from about 1 to about 7 carbon atoms, typically methyl or ethyl groups. Dodecyl trimethyl ammonium bromide, tetradecylpyridinium chloride, domiphen bromide, N-tetradecyl-4-ethyl pyridinium chloride, dodecyl dimethyl (2-phenoxyethyl)ammonium bromide, benzyl dimethylstearyl ammonium chloride, cetyl pyridinium chloride, quaternized 5-amino-1,3-bis(2-ethyl-hexyl)-5-methyl hexa hydropyrimidine, benzalkonium chloride, benzethonium chloride and methyl benzethonium chloride are exemplary of typical quaternary ammonium antibacterial agents. Other compounds are bis[4-(R-amino)-1-pyridinium] alkanes as disclosed in U.S. Pat. No. 4,206,215, issued Jun. 3, 1980, to Bailey, incorporated herein by reference. Stannous salts such as stannous pyrophosphate and stannous gluconate and other antimicrobials such as copper bisglycinate, copper glysinate, zinc citrate, and zinc lactate may also be included.
Also useful are enzymes, including endoglycosidase, papain, dextranase, mutanase, and mixtures thereof. Such agents are disclosed in U.S. Pat. No. 2,946,725, Jul. 26, 1960, to Norris et al. and in U.S. Pat. No. 4,051,234, Sep. 27, 1977 to Gieske et al., incorporated herein by reference. Specific antimicrobial agents include chlorhexidine, triclosan, triclosan monophosphate, and flavor oils such as thymol. Triclosan and other agents of this type are disclosed in Parran, Jr. et al., U.S. Pat. No. 5,015,466, issued May 14, 1991, and U.S. Pat. No. 4,894,220, Jan. 16, 1990 to Nabi et al., incorporated herein by reference. The water insoluble antimicrobial agents, water soluble agents, and enzymes may be present in the composition. The quaternary ammonium agents, stannous salts, and substituted guanidines are preferably present in the second dentifrice composition. These agents may be present at levels of from about 0.01% to about 1.5%, by weight of the dentifrice composition.
To further illustrate the invention and the advantages thereof, the following non-limiting examples are given.
In this example egg-shell (as a substitute for teeth) was stained with green/black tea stain.
In another experiment PEG400 phosphate ester (a polyethylene glycol phosphate ester) was mixed directly into the toothpaste without neutralization. Egg-shell was brushed with commercial toothpaste plus 20% PEG400 phosphate ester, then stained with green and black tea, and then brushed again with commercial tooth-paste plus 20% PEG400 phosphate ester.
In another experiment 20% sodium dodecyl sulphate (SDS) was mixed into the commercial toothpaste. The 20% SDS was used as a 100% powder.
In another experiment PEG1000 phosphate ester (a polyethylene glycol phosphate ester) was mixed directly into the toothpaste without neutralization.
In a separate test it was noted that treatment of egg-shell with SDS or PEG phosphate ester, then staining and then simple rinsing does not improve removal of stain compared to untreated egg-shell. This implies improved cleaning is not due to creation of anti-soiling layer, but due to better cleaning capability.
Comparison of
Thus, a low contact angle is observed for the crystal in pure water (i.e. good adsorption of the oil onto the crystal, which is undesirable) and a high contact angle is observed for the crystal in a solution of water and PEG 1000 phosphate ester (i.e. poor adsorption of the oil onto the crystal, which is desirable).
It is apparent that embodiments other than those expressly described above come within the spirit and scope of the present claims. Thus, the present invention is not defined by the above description, but rather is defined by the claims appended hereto.
This claims the benefit of U.S. Provisional Patent Application No. 60/943,490 filed Jun. 12, 2007 and is incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2438091 | Lynch | Mar 1948 | A |
| 2524218 | Bersworth | Oct 1950 | A |
| 2528378 | Mannheimer | Oct 1950 | A |
| 2530147 | Bersworth | Nov 1950 | A |
| 2658072 | Kosmin | Nov 1953 | A |
| 2826551 | Geen | Mar 1958 | A |
| 2874074 | Johnson | Feb 1959 | A |
| 2946725 | Norris et al. | Jul 1960 | A |
| 3033704 | Sherrill et al. | May 1962 | A |
| 3070510 | Cooley et al. | Dec 1962 | A |
| 3244724 | Guttmann | Apr 1966 | A |
| 3308067 | Diehl | Mar 1967 | A |
| 3332880 | Kessler et al. | Jul 1967 | A |
| 3538230 | Pader et al. | Nov 1970 | A |
| 3553139 | McCarty | Jan 1971 | A |
| 3598865 | Lew | Aug 1971 | A |
| 3599716 | Thompson | Aug 1971 | A |
| 3678154 | Widder et al. | Jul 1972 | A |
| 3681241 | Rudy | Aug 1972 | A |
| 3717630 | Booth | Feb 1973 | A |
| 3723322 | Diehl | Mar 1973 | A |
| 3793209 | Thompson | Feb 1974 | A |
| 3850831 | Hellsten et al. | Nov 1974 | A |
| 3862307 | Di Giulio | Jan 1975 | A |
| 3869412 | Waag | Mar 1975 | A |
| 3893929 | Basadur | Jul 1975 | A |
| 3912681 | Dickson | Oct 1975 | A |
| 3939911 | Maddox, Jr. et al. | Feb 1976 | A |
| 3948838 | Hinton, Jr. et al. | Apr 1976 | A |
| 3956198 | Bauer | May 1976 | A |
| 3959230 | Hays | May 1976 | A |
| 3959458 | Agricola et al. | May 1976 | A |
| 3964500 | Drakoff | Jun 1976 | A |
| 3976586 | Chakrabarti | Aug 1976 | A |
| 4001133 | Sorgenfrei et al. | Jan 1977 | A |
| 4008165 | Maddox, Jr. et al. | Feb 1977 | A |
| 4017410 | Sorgenfrei et al. | Apr 1977 | A |
| 4038027 | Kearney | Jul 1977 | A |
| 4049558 | Rasmussen | Sep 1977 | A |
| 4051234 | Gieske et al. | Sep 1977 | A |
| 4101457 | Place et al. | Jul 1978 | A |
| 4116984 | Prinzbach et al. | Sep 1978 | A |
| 4127489 | Pracht et al. | Nov 1978 | A |
| 4144226 | Crutchfield et al. | Mar 1979 | A |
| 4146495 | Crutchfield et al. | Mar 1979 | A |
| 4152416 | Spitzer et al. | May 1979 | A |
| 4152421 | Tsutsumi et al. | May 1979 | A |
| 4206215 | Bailey | Jun 1980 | A |
| 4235735 | Marco et al. | Nov 1980 | A |
| 4240919 | Chapman | Dec 1980 | A |
| 4261868 | Hora et al. | Apr 1981 | A |
| 4264580 | Barberio | Apr 1981 | A |
| 4278129 | Walton | Jul 1981 | A |
| 4287080 | Siklosi | Sep 1981 | A |
| 4321256 | Hasegawa et al. | Mar 1982 | A |
| 4350680 | Harvey et al. | Sep 1982 | A |
| 4364837 | Pader | Dec 1982 | A |
| 4391722 | Schwartz et al. | Jul 1983 | A |
| 4393935 | Walton | Jul 1983 | A |
| 4470923 | Koster | Sep 1984 | A |
| 4483779 | Llenado et al. | Nov 1984 | A |
| 4507219 | Hughes | Mar 1985 | A |
| 4525291 | Smith et al. | Jun 1985 | A |
| 4536317 | Llenado et al. | Aug 1985 | A |
| 4536318 | Cook et al. | Aug 1985 | A |
| 4536319 | Payne | Aug 1985 | A |
| 4541483 | Walton | Sep 1985 | A |
| 4548744 | Connor | Oct 1985 | A |
| 4557853 | Collins | Dec 1985 | A |
| 4559056 | Leigh et al. | Dec 1985 | A |
| 4565647 | Llenado | Jan 1986 | A |
| 4579681 | Ruppert et al. | Apr 1986 | A |
| 4597898 | Vander Meer | Jul 1986 | A |
| 4599188 | Llenado | Jul 1986 | A |
| 4614519 | Ruppert et al. | Sep 1986 | A |
| 4627977 | Gaffar et al. | Dec 1986 | A |
| 4664839 | Rieck | May 1987 | A |
| 4702857 | Gosselink | Oct 1987 | A |
| 4711730 | Gosselink et al. | Dec 1987 | A |
| 4721580 | Gosselink | Jan 1988 | A |
| 4728455 | Rerek | Mar 1988 | A |
| 4734099 | Cyprien | Mar 1988 | A |
| 4746456 | Kud et al. | May 1988 | A |
| 4752409 | Drapier et al. | Jun 1988 | A |
| 4770666 | Clauss | Sep 1988 | A |
| 4801395 | Chazard et al. | Jan 1989 | A |
| 4813482 | Walton | Mar 1989 | A |
| 4836949 | Klajnscek | Jun 1989 | A |
| 4859358 | Gabriel et al. | Aug 1989 | A |
| 4877896 | Maldonado et al. | Oct 1989 | A |
| 4886609 | Walton | Dec 1989 | A |
| 4891160 | Vander Meer | Jan 1990 | A |
| 4894220 | Nabi et al. | Jan 1990 | A |
| 4902499 | Bolish, Jr. et al. | Feb 1990 | A |
| 4933101 | Cilley et al. | Jun 1990 | A |
| 4968451 | Scheibel et al. | Nov 1990 | A |
| 4976879 | Maldonado et al. | Dec 1990 | A |
| 5015466 | Parran, Jr. et al. | May 1991 | A |
| 5019373 | Carter et al. | May 1991 | A |
| 5038864 | Dunleavy | Aug 1991 | A |
| 5064553 | Dixit et al. | Nov 1991 | A |
| 5098590 | Dixit et al. | Mar 1992 | A |
| 5104643 | Grollier et al. | Apr 1992 | A |
| 5114606 | van Vliet et al. | May 1992 | A |
| 5130043 | Prince et al. | Jul 1992 | A |
| 5160450 | Okahara et al. | Nov 1992 | A |
| 5236615 | Trinh et al. | Aug 1993 | A |
| 5280117 | Kerschner et al. | Jan 1994 | A |
| 5332528 | Pan et al. | Jul 1994 | A |
| 5370865 | Yamagishi et al. | Dec 1994 | A |
| 5405542 | Trinh et al. | Apr 1995 | A |
| 5413727 | Drapier et al. | May 1995 | A |
| 5415807 | Gosselink et al. | May 1995 | A |
| 5415860 | Beucherie et al. | May 1995 | A |
| 5510042 | Hartman et al. | Apr 1996 | A |
| 5510306 | Murray | Apr 1996 | A |
| 5534197 | Scheibel et al. | Jul 1996 | A |
| 5550274 | Reierson | Aug 1996 | A |
| 5554781 | Reierson | Sep 1996 | A |
| 5559261 | Sivik | Sep 1996 | A |
| 5565145 | Watson et al. | Oct 1996 | A |
| 5573709 | Wells | Nov 1996 | A |
| 5607680 | Brissonnet et al. | Mar 1997 | A |
| 5648584 | Murray | Jul 1997 | A |
| 5648585 | Murray et al. | Jul 1997 | A |
| 5686024 | Dahanayake et al. | Nov 1997 | A |
| 5710121 | Tracy et al. | Jan 1998 | A |
| 5798326 | Goldstein et al. | Aug 1998 | A |
| 5804542 | Scheper et al. | Sep 1998 | A |
| 5824289 | Stoltz | Oct 1998 | A |
| 5849960 | Singleton et al. | Dec 1998 | A |
| 5853710 | Dehan et al. | Dec 1998 | A |
| 5858343 | Szymczak | Jan 1999 | A |
| 5879469 | Avram | Mar 1999 | A |
| 5902574 | Stoner et al. | May 1999 | A |
| 5902778 | Hartmann et al. | May 1999 | A |
| 5939052 | White, Jr. et al. | Aug 1999 | A |
| 5968893 | Manohar et al. | Oct 1999 | A |
| 6017936 | Polson et al. | Jan 2000 | A |
| 6136221 | Reierson | Oct 2000 | A |
| 6149693 | Geib | Nov 2000 | A |
| 6150222 | Gardner et al. | Nov 2000 | A |
| 6187391 | Kataoka et al. | Feb 2001 | B1 |
| 6220352 | Walton | Apr 2001 | B1 |
| 6222077 | Singleton | Apr 2001 | B1 |
| 6242404 | Dahanayake et al. | Jun 2001 | B1 |
| 6271409 | Geib | Aug 2001 | B1 |
| 6297201 | Geib | Oct 2001 | B1 |
| 6342468 | Geib | Jan 2002 | B1 |
| 6387137 | Geib | May 2002 | B1 |
| 6525005 | Kravitz et al. | Feb 2003 | B1 |
| 6566313 | Hohenstein et al. | May 2003 | B1 |
| 6569261 | Aubay et al. | May 2003 | B1 |
| 6579466 | David et al. | Jun 2003 | B1 |
| 6593288 | Aubay et al. | Jul 2003 | B2 |
| 6767410 | Aubay et al. | Jul 2004 | B2 |
| 6767560 | Paek | Jul 2004 | B2 |
| 6864314 | Yeung et al. | Mar 2005 | B1 |
| 6924260 | Aubay | Aug 2005 | B2 |
| 7262153 | Shpakoff et al. | Aug 2007 | B2 |
| 7381695 | Minevski | Jun 2008 | B2 |
| 20030044469 | Viladot Petit et al. | Mar 2003 | A1 |
| 20030228339 | El-Nokaly et al. | Dec 2003 | A1 |
| 20040185027 | Reierson et al. | Sep 2004 | A1 |
| 20040247534 | Stoltz | Dec 2004 | A1 |
| 20050020466 | Man et al. | Jan 2005 | A1 |
| 20050184273 | Morelli et al. | Aug 2005 | A1 |
| 20060088482 | Wulknitz et al. | Apr 2006 | A1 |
| 20060093559 | Fabry | May 2006 | A1 |
| 20060135384 | Luu et al. | Jun 2006 | A1 |
| 20060159631 | Buch et al. | Jul 2006 | A1 |
| 20060217286 | Geoffroy et al. | Sep 2006 | A1 |
| 20070145617 | Finney et al. | Jun 2007 | A1 |
| 20070166243 | Yoshida et al. | Jul 2007 | A1 |
| 20080028986 | Futterer et al. | Feb 2008 | A1 |
| 20080095719 | Herrmann et al. | Apr 2008 | A1 |
| 20080220031 | Wunsch et al. | Sep 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 2829022 | Jan 1980 | DE |
| 0011984 | Jun 1980 | EP |
| 0066915 | Dec 1982 | EP |
| 0132043 | Jan 1985 | EP |
| 0132046 | Jan 1985 | EP |
| 0219048 | Apr 1987 | EP |
| 0488868 | Jun 1992 | EP |
| 0561656 | Sep 1993 | EP |
| 0909809 | Apr 1999 | EP |
| 1196523 | Apr 2002 | EP |
| 1196527 | Apr 2002 | EP |
| 1196528 | Apr 2002 | EP |
| 2236926 | Feb 1975 | FR |
| 2334698 | Jul 1977 | FR |
| 849433 | Sep 1960 | GB |
| 1314897 | Apr 1973 | GB |
| 1475798 | Jun 1977 | GB |
| 1498520 | Jan 1978 | GB |
| 1537288 | Dec 1978 | GB |
| 1578930 | Nov 1980 | GB |
| 2 192 194 | Jan 1988 | GB |
| 2 283 036 | Apr 1995 | GB |
| 2 283 755 | May 1995 | GB |
| 3157323 | Jul 1991 | JP |
| 047547 | Jan 1992 | JP |
| 6313271 | Nov 1994 | JP |
| 2003342140 | Dec 2003 | JP |
| 2005-013929 | Jan 2005 | JP |
| 9532272 | Nov 1995 | WO |
| 9532997 | Dec 1995 | WO |
| 9623859 | Aug 1996 | WO |
| 9623860 | Aug 1996 | WO |
| 9623861 | Aug 1996 | WO |
| 9742287 | Nov 1997 | WO |
| 9742288 | Nov 1997 | WO |
| 9742288 | Nov 1997 | WO |
| 9838973 | Sep 1998 | WO |
| 9841505 | Sep 1998 | WO |
| 2004082500 | Sep 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20080311055 A1 | Dec 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60943490 | Jun 2007 | US |
